Security key
59564R880
Biodexa Pharmaceuticals Plc - American Depositary Shares, each representing four hundred ordinary shares (BDRX)
CUSIP: 59564R880
Q1 2026 13F Holders as of 31 Mar 2026
- Security type / class
- Equity / American Depositary Shares, each representing four hundred ordinary shares
- Total 13F shares
- 368,950
- Total 13F value
- $227,974
- Share change
- +63,677
- SEC-reported price per share
- $0.62
- Number of holders
- 7
- Value change
- +$21,726
- Number of buys
- 3
- Number of sells
- 5
- Shares outstanding
- 1,881,632
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2026
Institutions
7
Top holders
7
BDRX full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2026
Previous quarter: Q4 2025
Biodexa Pharmaceuticals Plc SEC filings
Biodexa Pharmaceuticals Plc company facts
Broader feeds
Reporting periods
Holder history for CUSIP 59564R880
Recent filing periods:
Ownership snapshot
Top reported holders of BDRX - Biodexa Pharmaceuticals Plc - American Depositary Shares, each representing four hundred ordinary shares (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ARMISTICE CAPITAL, LLC
Disclosed value leader
SABBY MANAGEMENT, LLC
Comparable rows
9/9
Latest evidence
18 Mar 2026
13F
13D/G
3/4/5
Lead comparable stake: 10%
13D/G row: ARMISTICE CAPITAL, LLC
Showing 1-6 of 9 holder rows.
Quick read
ARMISTICE CAPITAL, LLC leads the comparable SEC ownership view at 10%.
9 of 9 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ARMISTICE CAPITAL, LLC's linked filing trail.
Comparable ownership
Top 5
ARMISTICE CAPITAL, LLC
10%
SABBY MANAGEMENT, LLC
9.9%
Simon Turton
0%
HRT FINANCIAL LP
0.56%
UBS Group AG
0.11%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 9 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC |
13F
13D/G
Company
|
10%
from 13D/G
|
$227,000
100,000 shares
|
— | 31 Dec 2025 |
| SABBY MANAGEMENT, LLC |
13D/G
13F
Company
|
9.9%
|
$493,974
217,600 shares
|
$0 | 31 Dec 2025 |
| Simon Turton |
3/4/5
Director
|
0%
|
$2,377
2,765 shares
|
— | 18 Mar 2026 |
| HRT FINANCIAL LP |
13F
Company
|
0.56%
|
$24,000
10,583 shares
|
— | 31 Dec 2025 |
| UBS Group AG |
13F
Company
|
0.11%
|
$4,767
2,100 shares
|
— | 31 Dec 2025 |
| GAMMA Investing LLC |
13F
Company
|
0.09%
|
$4,034
1,777 shares
|
— | 31 Dec 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
7
Shares
368,950
Rows available
7
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
8
Q1 2026 holders
7
Holder diff
-1
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 value | Q1 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend